Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy

Trauma
Written By Nick Martin, M.A.

Study

Evaluated long-term outcomes (17-74 months after) for trial using MDMA to treat chronic, treatment-resistant post-traumatic stress disorder (PTSD).

Results

14 out of 16 respondents maintained statistically and clinically significant improvements in symptom relief (two subjects relapsed). No subjects reported harm from the study.

Discussion

The therapeutic benefits of MDMA for treatment-resistant PTSD may last several years and be safe treatments.

Citation

Mithoefer MC, Wagner MT, Mithoefer AT, et al. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. Journal of Psychopharmacology. 2013;27(1):28-39. doi:10.1177/0269881112456611

Link To Study

Nick Martin, M.A.

Nick is a psychedelic facilitator and integration coach who holds a Masters in Counseling Psychology from Boston College.

Previous

The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder
Next

Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression